1-(2-(difluoromethoxy)pyridin-5-yl)ethanone | 1198166-10-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(2-(difluoromethoxy)pyridin-5-yl)ethanone
• 英文别名: 1-(6-(Difluoromethoxy)pyridin-3-yl)ethanone；1-[6-(difluoromethoxy)pyridin-3-yl]ethanone
• CAS: 1198166-10-7
• 化学式: C₈H₇F₂NO₂
• 分子量: 187.146
• InChiKey: JCMKOGOMMONSBN-UHFFFAOYSA-N

物化性质

• 沸点：
  264.2±35.0 °C(Predicted)
• 密度：
  1.252±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-(2-(difluoromethoxy)pyridin-5-yl)ethanone 、 2-(7-((2S,5R)-2,5-diethylpiperazin-1-yl)-4-methyl-5-oxo-4,5-dihydro-2H-pyrazolo[4,3-b]pyridin-2-yl)acetonitrile 在 N,N-二异丙基乙胺 、 (cyanomethyl)trimethylphosphonium iodide 作用下， 以 乙腈 为溶剂， 生成 2-(7-((2S,5R)-4-(1-(6-(difluoromethoxy)pyridin-3-yl)ethyl)-2,5-diethylpiperazin-1-yl)-4-methyl-5-oxo-4,5-dihydro-2H-pyrazolo[4,3-b]pyridin-2-yl)acetonitrile 、 2-(7-((2S,5R)-4-(1-(6-(difluoromethoxy)pyridin-3-yl)ethyl)-2,5-diethylpiperazin-1-yl)-4-methyl-5-oxo-4,5-dihydro-2H-pyrazolo[4,3-b]pyridin-2-yl)acetonitrile
  参考文献：
  名称：

  [EN] PYRAZOLOPYRIDINONE COMPOUNDS
  [FR] COMPOSÉS PYRAZOLOPYRIDINONES

  摘要：

  Disclosed herein is a compound of Formula (I) for activating T cells, promoting T cell proliferation, and/or exhibiting antitumor activity, a method of using the compounds disclosed herein for treating cancer, and a pharmaceutical composition comprising the same.

  公开号：

  WO2023011456A1
• 作为产物：
  描述：

  2-(二氟甲氧基)-5-溴吡啶 在 甲醇 、 sodium tetrahydroborate 、 四(三苯基膦)钯 作用下， 以 甲苯 为溶剂， 反应 0.67h， 生成 1-(2-(difluoromethoxy)pyridin-5-yl)ethanone
  参考文献：
  名称：

  [EN] PYRAZOLOPYRIDINONE COMPOUNDS
  [FR] COMPOSÉS PYRAZOLOPYRIDINONES

  摘要：

  Disclosed herein is a compound of Formula (I) for activating T cells, promoting T cell proliferation, and/or exhibiting antitumor activity, a method of using the compounds disclosed herein for treating cancer, and a pharmaceutical composition comprising the same.

  公开号：

  WO2023011456A1

文献信息

• CARBINOL DERIVATIVES HAVING CYCLIC LINKER
  申请人：Yamaguchi Yuki

  公开号：US20100048610A1

  公开（公告）日：2010-02-25

  [Object] To provide a novel LXRβ agonist that is useful as a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such as allergic skin diseases; diabetes; or Alzheimer's disease. [Solving Means] A carbinol compound represented by the following general formula (I) or salt thereof, or their solvate.

  提供一种新型的LXRβ激动剂，可用作预防和/或治疗动脉粥样硬化；动脉硬化，如糖尿病引起的动脉硬化；血脂异常；高胆固醇血症；与脂质相关的疾病；由炎性细胞因子引起的炎症性疾病；过敏性皮肤病；糖尿病；或阿尔茨海默病的治疗剂。【解决手段】以下一般式（I）所表示的羟甲基化合物或其盐，或其溶剂化合物。
• Carbinol derivatives having cyclic linker
  申请人：Kowa Company, Ltd.

  公开号：US08153634B2

  公开（公告）日：2012-04-10

  [Object] To provide a novel LXRβ agonist that is useful as a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such as allergic skin diseases; diabetes; or Alzheimer's disease. [Solving Means] A carbinol compound represented by the following general formula (I) or salt thereof, or their solvate.

  【目标】提供一种新型的LXRβ激动剂，可用作预防和/或治疗动脉粥样硬化、动脉硬化（如糖尿病引起的动脉硬化）、血脂异常、高胆固醇血症、与脂质相关的疾病、由炎性细胞因子引起的炎症性疾病、过敏性皮肤病、糖尿病或阿尔茨海默病的治疗剂。 【解决方法】以下通式（I）所表示的羟基甲基化合物或其盐，或其溶剂。
• [EN] FUSED HETEROCYCLIC DERIVATIVES<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES CONDENSÉS
  申请人：JANSSEN SCIENCES IRELAND UNLIMITED CO

  公开号：WO2022253255A1

  公开（公告）日：2022-12-08

  The application describes fused heterocycle derivative compounds, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment of diseases associated with HBV infection.

  该申请描述了融合杂环衍生物化合物，包括这些化合物的制药组合物，制备这些化合物的化学过程以及它们在治疗与HBV感染相关的疾病中的应用。
• SUBSTITUTED CARBINOL COMPOUND HAVING CYCLIC LINKER
  申请人：Kowa Company, Ltd.

  公开号：EP2281817A1

  公开（公告）日：2011-02-09

  It is to provide a novel LXRβ agonist that is useful as a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such as allergic skin diseases; diabetes; or Alzheimer's disease. It is a carbinol compound represented by the following general formula (I) or salt thereof, or their solvate.

  本发明旨在提供一种新型 LXRβ 激动剂，可作为动脉粥样硬化、动脉硬化（如糖尿病引起的动脉硬化）、血脂异常、高胆固醇血症、血脂相关疾病、由炎性细胞因子引起的炎症性疾病、皮肤病（如过敏性皮肤病）、糖尿病或阿尔茨海默病的预防和/或治疗药物。 它是由以下通式(I)或其盐或它们的溶解物所代表的醇化合物。
• US8153634B2
  申请人：——

  公开号：US8153634B2

  公开（公告）日：2012-04-10